Pertussis vaccine
Highest phase reached
Phase 3
Drug type
Vaccine component
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Vaccine component
- Drug name
- Pertussis vaccine
- adsorbed purified pertussis vaccine
- Adsorbed purified pertussis vaccine
- bordetella pertussis
- Bordetella pertussis
- haemophilus pertussis whole
- Haemophilus pertussis whole
- hemophilus pertussis whole
- Hemophilus pertussis whole
- microbe de la coqueluche whole
- Microbe de la coqueluche whole
- pertussis purified antigen
- pertussis vaccine
- Pertussis vaccine
- Pertussis, purified antigen
- ChEMBL ID
- CHEMBL2109219
- RxNorm IDs (RxCUI)
- 8080
- J07AJ02
- J07AJ52
Sources for recorded values
- First in class
- No
- Orphan designation
- No
- Condition
- Whooping Cough
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000650
- Subject identifier
- D014917
- Condition
- Pneumococcal Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000772
- Subject identifier
- D011008
- Condition
- Multiple Sclerosis, Relapsing-Remitting
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003929
- Subject identifier
- D020529
- Condition
- Tetanus
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005593
- Subject identifier
- D013742
- Condition
- Typhoid Fever
- Highest recorded phase
- 1
- Condition identifier
- EFO:0006789
- Subject identifier
- D014435
- Condition
- Meningitis, Meningococcal
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001040
- Subject identifier
- D008585
- Condition
- Streptococcal Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001476
- Subject identifier
- D013290
- Condition
- Alzheimer Disease
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0004975
- Subject identifier
- D000544
- Condition
- Multiple Sclerosis
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005301
- Subject identifier
- D009103
- Condition identifier
- EFO_0000650
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000772
- Highest recorded phase
- 1
- Condition identifier
- EFO_0005593
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001476
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004975
- Condition identifier
- MONDO_0005077
- Event
- congenital arterial malformation
- Reports
- 2
- Reporting signal score
- 14.1932
- Event
- cytogenetic abnormality
- Reports
- 2
- Reporting signal score
- 11.0925
- Event
- gestational diabetes
- Reports
- 3
- Reporting signal score
- 13.9675
- Event
- postpartum haemorrhage
- Reports
- 2
- Reporting signal score
- 10.8563
- Event
- ventricular septal defect
- Reports
- 3
- Reporting signal score
- 12.9691
- Event
- viith nerve paralysis
- Reports
- 3
- Reporting signal score
- 14.3269
- NCT00004799
- NCT00004800
- NCT04793620
- NCT05116241
- NCT00329901
- NCT00488826
- NCT01262924
- NCT04766086
- NCT05028634
- NCT05183516
- NCT05613205
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (36)
- A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine
- A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
- A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
- A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.
- Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults
- Bordetella Pertussis Colonisation Challenge Study
- Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infants
- Establishing a Controlled Human Infection Model of Bordetella Pertussis
- Establishing a Controlled Human Infection Model of Pertactin-deficient Bordetella Pertussis
- Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan
- Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
- Immunogenicity and Safety of the Concomitant Administration of a Tdap Vaccine and Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 11-25 Years
- Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
- Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines
- Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks
- Pertussis (Tdap) Vaccination in Pregnancy
- Pertussis Acellular Vaccine Adjuvanted With TQL1055
- Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Acellular and Whole-Cell Pertussis Vaccines
In development for (9)
- Alzheimer disease Phase 1
- Meningococcal meningitis Phase 3
- Multiple sclerosis Phase 3
- Pertussis Phase 3
- Pneumococcal infection Phase 1
- Relapsing-remitting multiple sclerosis Phase 3
- Streptococcal infection Phase 2
- Tetanus Phase 3
- Typhoid fever Phase 1